ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.
NYS Entity Status
NYS Filing Date
JUNE 19, 2013
NYS DOS ID#
CORPORATION SERVICE COMPANY
80 STATE STREET
ALBANY, NEW YORK, 12207-2543
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - CHESAPEAKE PHARMACEUTICAL PACKAGING INDIANA, INC.
AROUND THE WEB
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
- Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand
By Frank Vinluan - Friday Aug 25, 2017
In these politically divided times, Americans this week found near universal agreement on one thing: A celestial event that plunges a summer day into temporary darkness is a captivating experience. The totality of the solar eclipse lasted less than 3 minutes. If you missed it, you’ll have to wait until 2024 for the next one. […]
- A Drug Maker Spends Big in Washington to Make Itself Heard
By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017
Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Considering the Side Effects of Drugmakers’ Money-Back Guarantees
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Jul 10, 2017
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.